Cover Image
市場調查報告書

內臟痛覺:開發中產品分析

Visceral Pain - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 283207
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
內臟痛覺:開發中產品分析 Visceral Pain - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 58 Pages
簡介

所謂內臟痛覺是指內臟發生的傷害性疼痛之一。主要症狀有微微的疼痛感、絞痛、擴大般的痛覺等。主要治療藥有止痛藥(麻醉·NSAID(非甾體抗炎藥物)及其它)和修飾藥(三環系抗憂鬱劑·抗痙攣藥及其它)等。

本報告提供全球各國治療內臟痛覺所用的開發中產品開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

內臟痛覺概要

治療藥的開發

  • 內臟痛覺開發中產品:概要
  • 內臟痛覺開發中產品:比較分析

各企業開發中的內臟痛覺治療藥

各大學/研究機關研究中的內臟痛覺治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

內臟痛覺治療藥:開發中的產品一覽(各企業)

內臟痛覺治療藥:研究中的產品一覽(各大學/研究機關)

內臟痛覺治療藥的開發企業

  • Addex Therapeutics Ltd
  • Astellas Pharma Inc.
  • Chromocell Corporation
  • GIcare Pharma Inc
  • Grunenthal GmbH
  • Medestea Research & Production S.p.A.
  • Neurim Pharmaceuticals Ltd
  • Pfizer Inc.

內臟痛覺:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

內臟痛覺治療藥:暫停中的計劃

內臟痛覺治療藥:開發中止的產品

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8432IDB

Summary

Global Markets Direct's, 'Visceral Pain - Pipeline Review, H2 2016', provides an overview of the Visceral Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Visceral Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Visceral Pain and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Visceral Pain
  • The report reviews pipeline therapeutics for Visceral Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Visceral Pain therapeutics and enlists all their major and minor projects
  • The report assesses Visceral Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Visceral Pain

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Visceral Pain
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Visceral Pain Overview
  • Therapeutics Development
    • Pipeline Products for Visceral Pain - Overview
    • Pipeline Products for Visceral Pain - Comparative Analysis
  • Visceral Pain - Therapeutics under Development by Companies
  • Visceral Pain - Therapeutics under Investigation by Universities/Institutes
  • Visceral Pain - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Visceral Pain - Products under Development by Companies
  • Visceral Pain - Products under Investigation by Universities/Institutes
  • Visceral Pain - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Astellas Pharma Inc.
    • Chromocell Corporation
    • GIcare Pharma Inc
    • Grunenthal GmbH
    • Medestea Research & Production S.p.A.
    • Neurim Pharmaceuticals Ltd
    • Pfizer Inc.
  • Visceral Pain - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ASP-7663 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CC-8464 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GIC-1002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MED-1101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NeuP-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • piromelatine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PR-38 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-656570 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SBFI-26 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Activate OXTR for Oncology and Abdominal Pain - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Visceral Pain - Dormant Projects
  • Visceral Pain - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Visceral Pain, H2 2016
  • Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Visceral Pain - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Visceral Pain - Pipeline by Astellas Pharma Inc., H2 2016
  • Visceral Pain - Pipeline by Chromocell Corporation, H2 2016
  • Visceral Pain - Pipeline by GIcare Pharma Inc, H2 2016
  • Visceral Pain - Pipeline by Grunenthal GmbH, H2 2016
  • Visceral Pain - Pipeline by Medestea Research & Production S.p.A., H2 2016
  • Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H2 2016
  • Visceral Pain - Pipeline by Pfizer Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Visceral Pain - Dormant Projects, H2 2016
  • Visceral Pain - Dormant Projects (Contd..1), H2 2016
  • Visceral Pain - Dormant Projects (Contd..2), H2 2016
  • Visceral Pain - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Visceral Pain, H2 2016
  • Number of Products under Development for Visceral Pain - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top